Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Pharmacokinetic Study of IMX-110 in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Pharmacokinetic Study of IMX-110 in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Dec 2018

At a glance

  • Drugs IMX-110 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Immix Biopharma Australia
  • Most Recent Events

    • 10 Dec 2018 According to an Immix Biopharma media release, the company is awaiting additional preliminary efficacy readouts from patients in cohorts (dose-levels) 3 and 4 after which recruitment in cohort 5 will be initiated.
    • 06 Aug 2018 According to an Immix Biopharma media release, first two patients have been dosed in this trial.
    • 27 Feb 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top